Ovarian Germ Cell Cancer

主要目的： 1.评估BGB-B2033在晚期或转移性HCC、产生AFP的GC、性腺外卵黄囊肿瘤、非无性细胞瘤或GPC3阳性鳞状NSCLC受试者中的安全性和耐受性 2.确定BGB-B2033的MTD或MAD和RP2D

The goal of this observational case-control study is to learn about the circulating and tissue microRNA expression, imaging and radiomic profiles of malignant ovarian germ cell tumours (MOGCT) compared to patients with a benign OGCT and no ovarian pathology.
The main question[s] it aims to answer are:
To understand the circulating miRNA expression of malignant ovarian germ cell tumours (MOGCTs) compared to those with benign ovarian germ cell tumours (BOGCTs)
To understand the imaging profile of MOGCTs compared to that of BOGCTs
To establish the relationship between serum and plasma miRNA expression in response to treatment and relapse of disease
To discover if miRNA expression correlates with radiomic features of OGCTs on both ultrasound and MRI
To see if we can link the micro RNAs in tumour samples to those found in blood samples, and to find a plausible explanation for why these micro RNAs are raised (in terms of the tumour biology itself).aims
Participants will have serial blood tests at different time points in their care to assess how circulating miRNA levels are affected by treatment and/or remission and/or relapse. If they have surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their mass.
Researchers will compare the circulating miRNA profile of patients with a benign ovarian germ cell tumour and no ovarian pathology to see where the differences lie. If a patient with a BOGCT requires surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their benign mass.

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes.